ClinicalTrials.gg
RecruitingNCT06523140AUSTRAALUpdated Aug 22, 2025

Management of COPD Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exacerbations

An interventional study of Boracare remote monitoring solution in COPD, sponsored by Biosency. Recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Biosency · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.

Planned enrollment
97th of 286
380 · median 138
Started
2024
with 17 others
No phase
158 of 406
37 open now
Primary completion
2027-12
later than 49 of 80 live
Registered
363rd of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 97th largest by planned enrollment of the 286 interventional ones that give a count, is one of 18 that started in 2024, is one of 158 with no phase, reaches primary completion later than 49 of the 80 other live ones, and was the 363rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone (control group) on the total number of hospital days per patient for respiratory deterioration over 12 months of follow-up.

The main question it aims to answer is: Does remote monitoring of COPD patients reduce the average annual length of hospitalization for exacerbations of COPD patients?

All participants will benefit a conventional clinical follow-up.

Participants in experimental group will also benefit from the Bora care remote monitoring system.

Read the detailed description

Control group (control): conventional follow-up For the target population (frequent exacerbating COPD patients), the usual follow-up includes two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of HAS (National Authority for Health) and SPLF (French-Language Society of Pneumology).

Experimental group (conventional monitoring + remote monitoring):

The patients will be subject to conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. The Bora care remote monitoring system includes a BoraBand wristband measuring vital signs at home, the Bora Connect platform for caregiver visualization of data and the BVS3 score for early detection of COPD exacerbations. Patients are monitored daily remotely by Case Managers (nurses trained in Bora Care solution), who, when the BVS3 > 3 alert is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then alert the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription.

The Case Manager re-evaluates the situation after 48 hours and 96 hours if necessary and forwards the information to the pulmonologist. The nature of the transmission of information (telephone or email) between the Case Manager and the pulmonologist in case of an alert is defined when the patient is included by the pulmonologist. If desired, remotely monitored patients will be able to access the Bora Connect interface provided for patients (restricted viewing of data).

03

Conditions studied

  • COPD

Keywords

  • Remote monitoring
  • COPD
  • Prevention
  • Exacerbations
  • Patient quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age with defined according to the recommendations of the SPLF, whose level of respiratory function in a stable state is known (measured less than 12 months), recruited in pulmonology
  • Patient who has been hospitalized for COPD exacerbation in the previous 12 months
  • Informed patient who has signed consent,
  • Patient enrolled in a social security scheme (Art L1121-11 of the CSP)

Exclusion criteria

Exclusion Criteria:

  • Presence of a comorbidity considered unstable or very severe by the investigator.
  • Patient with psychological frailties,
  • Patient already included in another interventional trial,
  • Patient who does not speak French and is unable to use the Bora Band tool and without access to a caregiver,
  • Patient protected under guardianship or unable to give free and .
  • Pregnant or nursing woman
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • No intervention
    Control group

    Conventional follow-up: two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of SAH and SPLF.

  • Experimental
    Experimental group

    Patients will receive conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. Patients are monitored daily remotely by Case Managers, who, when the BVS3-3 alarm is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then notify the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription. The Case Manager re-evaluates the situation at 48h and 96h if necessary and forwards the information to the pulmonologist.

    Device: Boracare remote monitoring solution

Interventions

  • DeviceBoracare remote monitoring solution

    Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations

06

What researchers measure

Primary outcomes

  1. Demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations compared to conventional follow-up.

    Number of hospital days for respiratory deterioration per patient over 12 months.

    Time frame: 1 year

Secondary outcomes

  1. Evaluate the effect of the device on the number of hospitalizations per patient.

    Number of hospitalizations within 12 months of implementation of Bora Care remote monitoring.

    Time frame: 1 year

  2. Evaluate the effect of the device on the average length of stay.

    Average length of stay in hospital within 12 months of the implementation of Bora Care.

    Time frame: 1 year

  3. Assess the overall quality of life of patients at baseline and at the end of the trial. (1)

    Score from CAT (Chronic Obstructive Pulmonary Disease Assessment Test) questionnaire to assess the quality of life collected at Day 0, M6, M12.

    Time frame: 1 year

  4. Assess the overall quality of life of patients at baseline and at the end of the trial. (2)

    Score from Short Form 36 (SF36) quality of life assessment questionnaire to assess the quality of life collected at Day 0, M6, M12.

    Time frame: 1 year

  5. Assess the overall quality of life of patients at baseline and at the end of the trial. (3)

    Score from EXACT E-RS (Evaluating Respiratory Symptoms) symptom assessment questionnaire to assess the quality of life collected at Day 0, M6, M12.

    Time frame: 1 year

  6. Assess the conformity of use of the Bora Care device.

    Number of hours spent wearing the Bora Connect bracelet normalized by the total number of hours spent in the remote monitoring session, information collected via the Bora Care tool.

    Time frame: 3 years

  7. Assess the impact of the device on the organisation of care. (1)

    Number and nature of emergency, resuscitation, consultations and teleconsultations with the pulmonologist or attending physician.

    Time frame: 3 years

  8. Assess the impact of the device on the organisation of care. (2)

    Duration of emergency, resuscitation, consultations and teleconsultations with the pulmonologist or attending physician.

    Time frame: 3 years

  9. Assess the impact of the device on the organisation of care. (3)

    Number and nature of follow-up examinations and new pathologies detected during follow-up.

    Time frame: 3 years

  10. Assess the impact of the device on the quality of support. (1)

    Number and nature of prescribed pharmacological treatments and prescribed oxygen therapy.

    Time frame: 3 years

  11. Assess the impact of the device on the quality of support. (3)

    Duration of prescribed pharmacological treatments and prescribed oxygen therapy.

    Time frame: 3 years

  12. Assess patient and caregiver satisfaction with the device. (1)

    Subjective assessment by the patient of the device, the reassurance provided by the device, the assistance to resume physical activity provided by the device, obtained using satisfaction questionnaires at M6 and M12.

    Time frame: 1 year

  13. Assess patient and caregiver satisfaction with the device. (2)

    Subjective assessment by the patient of the overall quality of follow-up obtained using a detailed questionnaire (Likert scale) and an open-ended question about possible improvements at M6 and M12.

    Time frame: 1 year

  14. Assess patient and caregiver satisfaction with the device. (3)

    Subjective assessment by caregivers of the Bora Care solution's impact on patient care using questions about organizational impacts and improved quality of care provided by the device, obtained using a satisfaction questionnaire at M6 and M12.

    Time frame: 1 year

  15. Evaluate the performance of the warning device in the early detection of exacerbations.

    The number and nature of the alerts issued by the Bora Care solution, the number and nature of the actions taken following the alert specified in the alert management tool in the Bora Connect tool.

    Time frame: 3 years

  16. Identify new markers of exacerbations or other clinical events.

    Alert performance in detecting exacerbations and other medical events by calculating alert sensitivity and specificity.

    Time frame: 3 years

07

Study locations

3 of 10 sites recruiting
  • CHU de Brest
    Brest, Brittany Region 29200, France
    Recruiting
    • · Contact02 98 22 33 33
    • Christophe GUT GOBERT, MD · Principal investigator
  • Centre Hospitalier Bretagne Atlantique
    Vannes, Brittany Region 56000, France
    Recruiting
    • · Contact02 97 01 41 41
    • Tiphaine GUY, MD · Principal investigator
  • Centre Hospitalier de Chartres
    Le Coudray, Centre-Val de Loire 28630, France
    Not yet recruiting
    • · Contact02 37 30 30 30
    • Anissa BERRAIES, MD · Principal investigator
  • Centre Hospitalier Verdun
    Verdun, Grand Est 55100, France
    Not yet recruiting
    • · Contact03 29 83 84 85
    • Jean Claude CORNU, MD · Principal investigator
  • Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
    Lille, Hauts-de-France 59000, France
    Not yet recruiting
    • · Contact03 20 22 50 54
    • Arnaud CHAMBELLAN, MD · Principal investigator
  • Clinique du Millénaire
    Montpellier, Occitanie 34000, France
    Not yet recruiting
    • · Contact04 99 53 60 00
    • François BUGHIN, MD · Principal investigator
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse, Occitanie 31300, France
    Not yet recruiting
    • · Contact05 61 77 22 33
    • Sandrine PONTIER, MD · Principal investigator
  • Hôpital Européen Marseille
    Marseille, Provence-Alpes-Côte d'Azur Region 13003, France
    Not yet recruiting
    • · Contact04 13 427 000
    • Hervé PEGLIASCO, MD · Principal investigator
  • Hôpital de la Pitié Salpêtrière - AP-HP
    Paris, Île-de-France Region 75013, France
    Not yet recruiting
    • · Contact01 42 16 00 00
    • Jesus GONZALEZ, MD · Principal investigator
  • Hôpital Cochin - AP-HP
    Paris, Île-de-France Region 75014, France
    Recruiting
    • · Contact01 58 41 21 53
    • Nicolas ROCHE, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Not applicable. Data are not intended to be shared with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 37 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 26, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06523140
Lead sponsor
Biosency
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Nov 20, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 22, 2025

Study contacts

Alexis TOULLEC
Contact
clinical@biosency.com
02 21 65 70 01 ext. +33
Nicolas ROCHE, MD
principal investigator · Hôpital Cochin, AP-HP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion